Navigation Links
PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies
Date:2/24/2009

INDIANAPOLIS, Feb. 24 /PRNewswire/ -- PDS Biotechnology today announced that the company has obtained an exclusive license from Merck Eprova AG to utilize Merck Eprova's proprietary chiral lipid DOTAP Chloride in Versamune(TM)-HPV and other products in development based on the Versamune(TM) technology. The use of enantiomerically pure DOTAP Chloride shows enhanced adjuvant activity compared to the racemate. Merck Eprova AG will be providing enantiomerically pure DOTAP Chloride manufactured under cGMP for use in clinical and commercial drug products developed with PDS Biotechnology's Versamune(TM) nanoparticle technology. PDS Biotechnology will own the intellectual property rights to products incorporating the chiral DOTAP lipids for immunotherapeutic applications.

Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers caused by infection with the human papilloma virus (HPV) include cervical, head and neck and anal cancers. No cures exist for these cancers. Based on promising in vivo and in vitro efficacy data, PDS Biotechnology has been awarded grants by the US National Institutes of Health/National Cancer Institute to develop Versamune(TM)-HPV and Versamune(TM)-Melanoma. Versamune(TM)-Melanoma is being developed to treat melanoma, which is the most aggressive form of skin cancer.

PDS Biotechnology's Versamune(TM) nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen-presenting cells of the immune system. Simultaneously it acts as a strong immune system activator (adjuvant) without the inflammatory side effects induced by current adjuvants. The result is simple, safe and cost effective nanotechnology-based drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular protein formulated with Versamune(TM).

PDS Biotechnology Corporation (www.pdsbiotech.com) is an Indiana-based biotechnology company applying the company's proprietary Versamune(TM) nanotechnology drug platform technology to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.

Merck Eprova AG (www.merckeprova.com), located in Schaffhausen, Switzerland, is a wholly owned subsidiary of Merck KGaA located in Darmstadt, Germany. Merck Eprova AG specializes in the development and production of cGMP grade, highly purified and characterized Drug Delivery Compounds such as cationic lipids, PEGs, PEG-lipids, and phospholipids. In addition Merck Eprova AG is a centre of excellence for reduced folates in the pharmaceutical and nutritional field and the world's leading supplier of reduced folates.


'/>"/>
SOURCE PDS Biotechnology
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
2. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
3. Yongye Biotechnology International to Expand its Network of Branded Stores
4. Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders
5. Yongye Biotechnology to Present at Roth Conference
6. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
7. Energy, Biotechnology and Agribusiness Veterans Form SG Biofuels to Develop Jatropha as Low-Cost, Sustainable Oil
8. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
9. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
10. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
11. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):